Antibiotice Ia (ATB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Antibiotice Ia (ATB) has a cash flow conversion efficiency ratio of -0.042x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON-39.31 Million ≈ $-9.03 Million USD) by net assets (RON944.64 Million ≈ $216.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Antibiotice Ia (ATB) balance sheet quality index to measure how much of total assets are equity-financed.
Antibiotice Ia - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Antibiotice Ia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Antibiotice Ia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antibiotice Ia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eupraxia Pharmaceuticals Inc
TO:EPRX
|
-0.037x |
|
Jiangsu Tianmu Lake Tourism Co Ltd
SHG:603136
|
0.043x |
|
Xiamen R&T Plumbing Technology Co Ltd
SHE:002790
|
0.021x |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
0.008x |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
-0.014x |
|
Interarch Building Products Limited
NSE:INTERARCH
|
0.048x |
|
Jiangsu Jinling Sports Equipment Co Ltd
SHE:300651
|
0.053x |
|
Shenzhen Magic Design & Decoration Engineering Co Ltd
SHE:002856
|
3.139x |
Annual Cash Flow Conversion Efficiency for Antibiotice Ia (2022–2025)
The table below shows the annual cash flow conversion efficiency of Antibiotice Ia from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Antibiotice Ia (ATB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | RON932.07 Million ≈ $214.02 Million |
RON72.44 Million ≈ $16.63 Million |
0.078x | -26.95% |
| 2024-09-30 | RON894.31 Million ≈ $205.35 Million |
RON95.15 Million ≈ $21.85 Million |
0.106x | -26.42% |
| 2023-09-30 | RON846.96 Million ≈ $194.48 Million |
RON122.46 Million ≈ $28.12 Million |
0.145x | -19.82% |
| 2022-09-30 | RON641.43 Million ≈ $147.28 Million |
RON115.66 Million ≈ $26.56 Million |
0.180x | -- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more